In an ancillary study of the VITAL trial, researchers compared how supplemental vitamin D3 and placebo affected fracture risk. VITAL investigated whether 2000 IU of supplemental vitamin D3 per day, 1 g of n−3 fatty acids per day, or both would prevent cardiovascular disease and cancer in men aged 50 years or older and women aged 55 years or older in the United States. The researchers did not recruit based on osteoporosis, low bone mass, or vitamin D deficiency. Participants reported incident fractures on annual questionnaires and researchers evaluated incident total, nonvertebral, and hip fractures as primary endpoints.
Among more than 25,000 participants, supplemental vitamin D3 did not have a significant effect on nonvertebral fractures, hip fractures, or total fractures compared with placebo. Researchers observed no modification of the treatment effect or differences in adverse events according to serum 25-hydroxyvitamin D (25[OH]D) levels or baseline characteristics, including age, race or ethnic group, sex, or body mass index (BMI).
Learn more about vitamin D deficiency and related disorders.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori. Rapid Review Quiz: Vitamin D - Medscape - Sep 06, 2022.